Date Time
Biotech company founded by University of Toronto researchers secures US$85 million in financing Juan Carlos Zúñiga-Pflücker (left), of the Temerty Faculty of Medicine and Sunnybrook Health Sciences Centre, and Peter Zandstra, who is now at UBC, founded Notch Therapeutics at U of T in 2018.
Notch was founded in 2018 by two pioneers of cell therapy research, Juan Carlos Zúñiga-Pflücker, chair of the department of immunology at the University of Toronto’s Temerty Faculty of Medicine and a senior scientist at Sunnybrook Health Sciences Centre, and Peter Zandstra, who was then at U of T and is now a professor at the University of British Columbia, but continues to collaborate with U of T’s Institute for Biomedical Engineering. The company was supported by MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine.
Vancouver biotech Notch Therapeutics raises US$85-million in venture funding theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.
Published: Feb 10, 2021
VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/ Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led by an exclusively healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine (CCRM); along with new investors EcoR1 Capital, a undisclosed leading global investment firm, Casdin Capital, Samsara BioCapital, and Amplitude Ventures. Proceeds from the financing will support the continuing development of Notch s portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company s proprietary Engineered Thymic Niche (ETN) platform. The financing will
Share this article
Share this article
VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ Notch Therapeutics Inc., a biotechnology company developing renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Chris Bond, Ph.D. as Senior Vice President, Preclinical and Translational Sciences. Dr. Bond joins Notch from Kite, where he most recently served as Vice President of Cellular Engineering. We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND, said David Main, President and Chief Executive Officer of Notch. Adding Chris to our leadership team will bolster our preclinical pipeline and translational research capabilities to accelerate development of the company s cell therapy candidates from discovery into clinical application.
The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Geoff Robins/The Globe and Mail
A tiny London, Ont., medical device company hoping to change how diabetes is treated has had a wild ride of late. Last Friday, stock in Sernova Corp. shot up 65 per cent on the TSX Venture Exchange, then nearly doubled on Monday, closing at $2.42 a share. At its peak, Sernova had a market capitalization of $630-million, making it one of Canada’s 15 most valuable publicly traded life sciences companies.